2. Academic Validation
  3. Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR

Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR

  • Bioorg Med Chem Lett. 2019 Feb 15;29(4):631-637. doi: 10.1016/j.bmcl.2018.12.043.
Wonken Choung 1,  Hui Jin Jung 1,  Deokmo Yang 1,  Eun Hye Nam 1,  Hyukjoon Choi 1,  Bo Ram Lee 1,  Min Park 1,  Su Min Jang 1,  Jae Soo Lim 1,  Woo Sik Kim 1,  Kyung-Hee Kim 2,  Jungwook Chin 2,  Kyungjin Jung 2,  Geumwoo Lee 2,  Eunmi Hong 2,  Tae-Ho Jang 2,  Jayhyuk Myung 1,  Seong Heon Kim 3
Affiliations

Affiliations

  • 1 Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea.
  • 2 New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea.
  • 3 Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea. Electronic address: rose1998@boryung.co.kr.
PMID: 30594432 DOI: 10.1016/j.bmcl.2018.12.043
Abstract

The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crystallography of BR101549 with PPARgamma ligand binding domain (LBD) revealed unique binding characteristics versus traditional TZD full agonists. The lead candidate, BR101549, has been found activating PPARgamma to the level of Pioglitazone in vitro and indeed has demonstrated its effects on blood glucose control in mouse proof-of-concept evaluation. The attempts to improve its metabolic stability profile through follow-up SAR including deuterium incorporation have been also described.

Keywords

Antidiabetics; Drug discovery; PPARgamma agonist.

Figures
Products